Serological Detection of Heat Shock Protein hsp27 in Normal and Breast Cancer Patients

Mariel A. Fanelli, F. Dario Cuello Carrión, Judith Dekker, Joop Schoemaker, and Daniel R. Ciocca

Laboratory of Reproduction and Lactation, Regional Center for Scientific and Technological Research, Mendoza 5500, Argentina [M. A. F., D. C. C., D. R. C.], and The Institute for Endocrinology, Reproduction and Metabolism, Medical Centre of the Vrije Universiteit, Amsterdam, the Netherlands [J. D., J. S.]

Abstract

Heat shock protein Mf, 27,000 (hsp27) is found in many human breast cancer cells and tissues; its expression is associated with the presence of estrogen receptors, lower cell proliferation, and resistance to certain chemotherapies. The purpose of this study was to assess whether hsp27 may be present in sera from women with primary breast cancer and to know whether autoantibodies to hsp27 may be found in these patients. The study was performed by Western blot analyzing sera from 42 normal premenopausal women, 20 normal postmenopausal women, and 36 breast cancer patients. hsp27 was clearly detected in sera by immunoblotting but only after immunoprecipitation. The mean hsp27 levels in cancer patients were higher than in the control patients; however, 66% of the breast cancer patients showed hsp27 within the normal range, indicating low sensitivity. Moreover, cancer patients with metastatic disease did not show significantly higher hsp27 levels than cancer patients without metastases. Serum hsp27 levels did not correlate with the hsp27 levels in tumor tissues detected by immunohistochemistry. Elevated CA 15-3 levels were not associated with high hsp27 values. Autoantibodies against hsp27 were not detected by immunoblotting in normal sera and in sera from breast cancer patients. As a consequence, serological determination of this biomarker is unlikely to be of utility in the detection and follow-up of breast cancer patients.

Introduction

Several biomarkers have been evaluated in serum from breast cancer patients. The primary use is in following the clinical course of the disease (detecting metastatic progression) and monitoring response to therapy (1-5). CA 15-3 is one of the most efficient tumor markers; it is defined by two monoclonal antibodies (DF3 and 115D8), and its specificity is about 95%, whereas its sensitivity is about 65% (6). To increase the sensitivity, a combination of tumor markers has been tested without significant results (5, 6). At present, there are not adequate tumor markers to detect early stages of breast cancer; therefore, they are not applicable for screening. There is still a need for additional serological biomarkers useful in breast cancer patients.

hsp27 belong to a family of proteins induced by heat shock and others stressful situations (e.g., hypoxia and anoxia, oxidant injury, and accumulation of damaged proteins). Many of the hsp2s are also constitutively expressed, playing important roles as molecular chaperones in normal cell function (7-9). We are particularly interested in one of the small hsp2s, hsp27, because this protein is estrogen-regulated and appears with increased frequency in human breast cancer tissues (10). The expression of hsp27 in breast cancer biopsies has been controversially associated with the clinical outcome of the disease (11-17). In a recent definitive study evaluating a large number of axillary lymph node-negative breast cancer patients, hsp27 did not appear as a clinically useful prognostic marker (18). The expression of this protein has not been associated with a response to tamoxifen in patients with advanced disease (19). Of interest is the in vitro and clinical data supporting the association of hsp27 with drug resistance in breast cancer cells and tissues (20-22). In addition, controversial associations of hsp27 expression with prognosis have been reported in several other malignant diseases (23-28).

hsp27 seems to function as a molecular chaperone and is involved in signal transduction pathways of cell regulators and in the development of resistance to stressful conditions. Most of hsp27 is found in the cytoplasm of breast tumor cells (29); however, in MCF-7 cells grown in the ascites fluid of nude mice, hsp27 is found in the apical cytoplasm of the cells, sometimes appearing in granules, suggesting secretion (30). In the present study, we have investigated whether hsp27 can be detected in serum samples from healthy women and from women with different stages of breast cancer to know whether quantitative detection of this protein could be a serviceable serological biomarker.

Materials and Methods

Study Population. The study involved 14 healthy premenopausal women, 20 postmenopausal women, and 30 women with breast cancer (6 premenopausal and 24 postmenopausal). Because hsp27 is estrogen-regulated during the menstrual cycle in normal human endometrium (31), three blood samples were taken from each of the healthy women at different stages of the menstrual cycle: menstrual phase (day 2), end of follicular

Received 1/30/98; revised 6/3/98; accepted 6/15/98.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

This work was supported by Grant BID 802/OC-AR PH 101 from the National Agency for Scientific and Technological Promotion of Argentina and by the Vrije Universiteit of Amsterdam.

To whom requests for reprints should be addressed, at Laboratory of Reproduction and Lactation, Casilla de Correo 855, 5500 Mendoza, Argentina. Phone: 54-61-286112; Fax: 54-61-287370; E-mail: cncyr@lanet.losandes.com.ar.

1 The abbreviations used are: hsp, heat shock protein; ER, estrogen receptor.
Table 1: Main characteristics of the study population

<table>
<thead>
<tr>
<th>Cases</th>
<th>Age (± SD)</th>
<th>Disease stage</th>
<th>Tumor type</th>
<th>ER content</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Premenopausal</td>
<td>14</td>
<td>34 ± 4</td>
<td>I-II</td>
<td>IDC</td>
</tr>
<tr>
<td>Postmenopausal</td>
<td>20</td>
<td>59 ± 9</td>
<td>IV</td>
<td>MUC</td>
</tr>
<tr>
<td>Breast cancer patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Premenopausal</td>
<td>6</td>
<td>39 ± 8</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>Postmenopausal</td>
<td>24</td>
<td>63 ± 11</td>
<td>15</td>
<td>9</td>
</tr>
</tbody>
</table>

* IDC, infiltrating ductal carcinoma; MUC, mucinous carcinoma.

Results

On immunoblot analysis using sera from breast cancer patients and normal sera, none of the sera tested showed a clear and distinct band with a Mr of 27,000 daltons. Therefore, to increase the sensitivity of the detection technique, immunoblot analysis was performed on sera after immunoprecipitation with a monoclonal antibody against hsp27. Under these conditions, a spe-
Serum hsp27 levels were evaluated in normal women and breast cancer patients. Bars, mean for each group. Co. Pre., control premenopausal women (n = 242); Co. Post., control postmenopausal women (n = 187); Ca. Pre., cancer premenopausal patients (n = 256); Ca. Post., cancer postmenopausal patients (n = 404); Ca. M-;, cancer patients without metastases (n = 263); Ca. M+; cancer patients with metastases (n = 501).

Table 2 CA15-3 and hsp27 levels in breast cancer patients

<table>
<thead>
<tr>
<th>Stage</th>
<th>Patients</th>
<th>CA 15-3 % &gt; 50 units/ml</th>
<th>hsp27 % &gt; 400 A</th>
</tr>
</thead>
<tbody>
<tr>
<td>I-II</td>
<td>20</td>
<td>5</td>
<td>20</td>
</tr>
<tr>
<td>IV</td>
<td>10</td>
<td>100</td>
<td>60</td>
</tr>
</tbody>
</table>

Table 3 hsp27 values in serum and tumor tissues from breast cancer patients

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>hsp27 in serum (A)*</th>
<th>ER</th>
<th>hsp27 in tissue</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Cytoplasm</td>
<td>Nuclear</td>
</tr>
<tr>
<td>1</td>
<td>409</td>
<td>+</td>
<td>3 + 3</td>
</tr>
<tr>
<td>2</td>
<td>202</td>
<td>+</td>
<td>2 + 2</td>
</tr>
<tr>
<td>3</td>
<td>357</td>
<td>NT</td>
<td>2 + 2</td>
</tr>
<tr>
<td>4</td>
<td>350</td>
<td>+</td>
<td>2 + 4</td>
</tr>
<tr>
<td>5</td>
<td>131</td>
<td>+</td>
<td>2 + 3</td>
</tr>
<tr>
<td>6</td>
<td>320</td>
<td>+</td>
<td>2 + 4</td>
</tr>
<tr>
<td>7</td>
<td>122</td>
<td>+</td>
<td>3 + 2</td>
</tr>
<tr>
<td>8</td>
<td>80</td>
<td>-</td>
<td>2 + 3</td>
</tr>
</tbody>
</table>

hsp27 serum values were then compared with CA 15-3 serum levels; in our study, all of the patients with high CA 15-3 values (≥50 units/ml) had advanced disease with distant metastases. As shown in Table 2, only 60% of the patients with distant metastases showed high hsp27 values (>400 A). Moreover, high hsp27 values were seen in 20% of the breast cancer patients without distant metastases (5% for CA 15-3 levels).

In eight of the breast cancer samples tested, we studied the paraffin blocks to correlate the hsp27 levels in the sera with the hsp27 expression levels in the tumor tissues (Table 3). No correlation was found in hsp27 expression levels in the sera and matched tumor tissues. High hsp27 levels were observed in 55% of ER+ patients and in 45% of ER- patients (data not shown).

Finally, no anti-hsp27 antibodies were detected on immunoblot analysis in the serum from the breast cancer patients examined (n = 11) and from normal controls (n = 5); however, other bands at Mr 32,800, 54,000, 61,800, and 67,000 were observed (sera from breast cancer patients).
Discussion

The hsp27 status of breast cancer patients has been investigated previously in cancer tissues, and the data have shown: (a) correlation between the presence of hsp27 and estrogen receptor (39, 40); (b) lack of prognostic significance in lymph node-negative patients (18); (c) an inverse correlation of hsp27 overexpression with cell proliferation (29); and (d) association of hsp27 with resistance to chemotherapy (20-22). However, there are no studies evaluating the presence of hsp27 in serum samples or the production of autoantibodies to hsp27 in breast cancer patients. hsp27 together with other hsps are molecular chaperones; they may be escorting proteins targeted to different cell compartments. hsps are mainly present in the cytoplasm but sometimes may be located in the nucleus and on the cell surface (7-10, 41). For example, hsp72 has been found expressed only on the cell surface of human tumor cells after a nonlethal heat stress, but not on normal cells (42). We can then speculate that under certain circumstances, hsps might be released to the circulation actively or in the clearance of cell contents that are liberated during cell replacement/renewal, and that they might also induce autoantibodies.

In the present study, we have not found autoantibodies against hsp27 in normal or in breast cancer patients; however, our observations are compatible with the presence of hsp27 in serum in human normal women and in women with breast cancer. In previous studies, autoantibodies against certain hsps (i.e., hsp60, hsp72, and hsp90) have been found, but not against hsp27 (35, 36). Moreover, to our knowledge, no autoantibodies against hsps have been detected in cancer diseases.

The quantity of hsp27 present in the serum is very low because the protein could be clearly detected only after enrichment by immunoprecipitation. hsp27 is found in many tissues, but higher expression is seen in estrogen-target tissues (10). We then asked whether the protein is in part released from these tissues to the blood with more predominance at certain stages of the menstrual cycle; in fact, more hsp27 content has been noted in the endometrium during the luteal phase of the menstrual cycle (31). Our study shows that hsp27 levels were rising from menstrual days to proliferative phase to luteal phase; however, these changes did not reach statistical significance.

Our study shows that immunoreactive hsp27 could also be found in sera from breast cancer patients. In general, higher hsp27 levels were observed in breast cancer patients than in the controls; however, 66% of the breast cancer patients showed hsp27 levels within the normal range, indicating low sensitivity. A lack of correlation was noted between hsp27 expression in the tumor tissues and the amount of immunoreactive hsp27 in corresponding serum samples. In addition, high hsp27 levels (≥400 A) were seen in only 60% (6 of 10) of the patients with distant metastases, and all of these patients had pathological CA 15-3 levels (≥50 units/ml). Therefore, serological determination of hsp27 is unlikely to be of utility in the detection and follow-up of breast cancer patients.

References


Serological detection of heat shock protein hsp27 in normal and breast cancer patients.

M A Fanelli, F D Cuello Carrión, J Dekker, et al.